Vascular Endothelial Growth Factor

Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity

PURPOSE

To explore the effect of resveratrol on B-cell leukemia/lymphoma-2 (Bcl-2) and vascular endothelial growth factor (VEGF) expression in rats with oxygen-induced retinopathy of prematurity (ROP).

METHODS

Seven-day-old Sprague-Dawley rats (N = 60) were randomly assigned to five groups. Group A received normal partial oxygen pressure and groups B, C, D, and E received 75% ± 2% oxygen for 5 days to induce ROP. The rats in groups C, D, and E were intragastrically treated with resveratrol (10, 30, and 60 mg/kg/d, respectively) once daily for 5 days. Rats were killed at 17 days of age and the retina was collected.

RESULTS

Western blot analysis revealed increased Bcl-2 protein expression in group B versus group A. Levels of Bcl-2 decreased with the increase of resveratrol concentration in groups C, D, and E. The optical density of Bcl-2 protein expression in group B was four times higher than that in group A (P < .01). When compared with group B, expression of Bcl-2 and VEGF in groups C, D, and E decreased in a dose-dependent manner. Significant differences in expression of Bcl-2 and VEGF were also noted among the three treatment groups with resveratrol (P < .01). After treatment with resveratrol at 10, 30, and 60 mg/kg/d, the inhibition rate of Bcl-2 expression was 11.1%, 38.1%, and 69.8% and that of VEGF expression was 3.4%, 23.0%, and 43.7%, respectively.

CONCLUSION

Resveratrol can significantly inhibit expression of Bcl-2 and VEGF in the retina of neonatal rats with oxygen-induced ROP. It may provide a protective effect on retinal neovascular diseases, including ROP.